HCPLive Network

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.


Further Reading
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah recently discovered the mechanism potentially triggering pancreatic cancer from the defects resulting from extrusion, the process through which cells are squeezed out of overcrowded tissue to die.
Adult male hypogonadism (HG) is the most common form of diminished gonadal activity in men. Most clinicians prescribe testosterone replacement therapy to treat primary HG, but other therapeutic options are available.
In March 2014, the Society of Surgical Oncology Susan G. Komen for the Cure Symposium focused on the literature on the epidemiology, molecular pathology, and therapy considerations of triple-negative breast cancer. The Annals of Surgical Oncology has published a summary of this work ahead of print.
More Reading